Biotech stock poised for major gains upon FDA approval of Casgevy, a groundbreaking gene editing treatment for sickle cell disease. With potential market value over $100 billion, investors eye this revolutionary therapy as a major catalyst for growth in the healthcare sector. Stay tuned for updates on FDA decision and stock market reaction.